Improving the management is very important in every other case and especially topics such as Brain Metastases in Oncogene-Addicted Non–Small-Cell Lung Cancer have been a serious issue. Patients with brain metastases typically have worse outcomes. As extracranial disease control improves with new systemic therapies, patient quality of life and morbidity following treatment of CNS metastasis are increasingly important.The marked intracranial activity of novel targeted therapies makes the optimal sequencing of systemic therapies with local treatment (eg, radiation or surgery for management of brain metastases) unclear.his stems from the improved CNS efficacy of newer-generation TKIs exhibited in recent clinical trials.
An important caveat is that almost 25% of patients in FLAURA and one-third of patients in ALEX had prior CNS radiation.or instance, intracranial ORRs range between 40% and 60% for alectinib, ceritinib, brigatinib, or lorlatinib after progression on crizotinib in patients with ALK-rearranged lung cancer.10 Intracranial response rates between 50% and 70% have been reported with osimertinib in patients with T790M-positive disease that has progressed on treatment with first-generation EGFR TKIs.
Further Improving the Management of Brain Metastases in Oncogene-Addicted Non–Small-Cell Lung Cancer is very much important. New techniques have helped improve the situation a lot.
https://ascopubs.org/doi/full/10.1200/JOP.19.00575
